Jupiter Orphan Therapeutics

[On Demand]

JOT a Clinical stage company focusing on CNS Diseases JOT is a virtually based company with a strong, experienced core management team. JOT utilizes the strength of its partners and advisors from both industry and academia JOT’s long-term focus is developing a treatment for Alzheimer’s Disease (AD), while in parallel develop one or more treatments for rare diseases. JOT’s unique resveratrol formulation, JOTROLTM, is the first product in the world to allow delivery of safe, therapeutic doses of resveratrol. JOTROLTM, is enabling JOT to use 1 product for multiple diseases. Less risk, more opportunities and faster to market.


Jupiter Orphan Therapeutics is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
JOTROL, highly bioavailable resveratrol
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1 (with multiple indications)
Jupiter Orphan Therapeutics, Inc.